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EDITORIAL REVIEW
Polycystic kidney disease: Clues to pathogenesis
Autosomal-dominant polycystic kidney disease (ADPKD),
largely neglected for several decades, has emerged in recent
years as the renal disease most likely to be understood from the
gene to the patient. Major breakthroughs have occurred in the
genetics of the disorder and new experimental data is providing
insights in the pathobiology of cyst formation (Table I).
Genetics of ADPKD
Localization of ADPKD gene
Prior to 1985 information on the genetics of ADPKD was
restricted to the simple concept of transmission of an autosomal
dominant disorder. In 1985 Reeders et al applied the techniques
of reverse genetics to this disorder and linkage was detected
between the ADPKD gene and the 3' hypervariable region (3'
HVR) of the alpha globin locus [I]. This linkage placed the
ADPKD gene (ADPKDI) on the short arm of chromosome 16.
Subsequent investigation has resulted in the development of
closely-linked flanking probes which more precisely localize the
gene to the tip of this chromosome [2]. This discovery which
delineates the location of the ADPKD gene has enlarged the
clinician's diagnostic repertoire for this disease, and provides
the first step to ultimate isolation of the gene and its gene
product.
Prior to the availability of gene linkage analysis, the disorder
and hence the gene carrier state could only be diagnosed after
bilateral renal cysts were identified. This often imposed barriers
to effective genetic counselling, as the cysts were frequently
detected only after the childbearing years. In the last decade
this barrier to early diagnosis, and hence effectively-timed
genetic counselling, has been lowered substantially by the
improvement of imaging techniques with more sensitive ultra-
sonography and the use of computed tomography and magnetic
resonance imaging which permit the reliable detection of very
small renal cysts [3—5]. For example, in our family studies of
subjects at risk for ADPKD, 40% of children less than 20 years
of age who undergo abdominal ultrasonography have detectable
renal cysts, a percentage approaching the predicted frequency
of 50% in an at-risk population. In other words, screening
ultrasonography alone appears to detect about 80% of those
who on a statistical basis are likely to have the disease.
Similarly Bear et al estimate that 68% of children between ages
11 and 20 who have ADPKD have detectable cysts using
ultrasonography [6]. Most recently, Parfrey et al have demon-
strated that in individuals who are likely to have the ADPKD
gene by linkage techniques (ADPKDI; see below) and who are
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less than 30 years of age, only 17% did not have diagnostic
ultrasonography for ADPKD [7].
Nonetheless, despite these improvements in renal imaging
which permit earlier diagnosis, these methods are still depen-
dent upon the presence of detectable renal cysts. Localization
of the gene and the subsequent commercial availability of the
DNA probes have made diagnosis possible prior to the detec-
tion of any renal cysts. In fact, it is now possible to determine
the gene status of an at-risk fetus in utero [8]. Since the gene
itself has not yet been identified, the necessary prerequisites for
the application of gene linkage analysis must be present: the
presence of at least two affected individuals in order to deter-
mine the marker type segregating with ADPKD in the family;
the presence of informative marker types in the family, that is,
different types in affected and unaffected individuals; and a
family with the ADPKD gene located on chromosome 16, as
discussed later (Fig. 1). Individuals fulfilling all these criteria
can have the presence of the ADPKD gene predicted prior to
the occurrence of any phenotypic manifestation at 99 to 1 odds
rather than the 50/50 odds that would be predicted from the
principle of inheritance alone [9]. Moreover, as exemplified by
the study of Cobben et al, utilization of linkage analysis has
permitted expansion of the knowledge of phenotypic presenta-
tion of ADPKD to include the occurrence of congenital hepatic
fibrosis which previously had been believed to be largely
associated with autosomal-recessive polycystic kidney disease
[10].
Although these discoveries have provided new tools for
diagnosis, their role in screening and in prenatal diagnosis has
generated some controversies [II]. Resolution of these will
largely depend upon the development of effective early inter-
vention which will provide a therapeutic incentive for screen-
ing.
Genetic heterogeneity
Another major advance in the genetics of ADPKD was the
discovery that the clinical disorder which was assumed to result
from one gene defect could result from different genetic defects
[12—15]. All of the initial 100 families examined with the DNA
probes for the alpha globin region of chromosome 16 demon-
strated by linkage analysis that the putative gene was located on
chromosome 16, suggesting genetic homogeneity—one gene
defect for one disorder [2]. However, Kimberling et al then
reported a large Sicilian family whose gene for ADPKD was not
linked to markers for the alpha globin region of chromosome 16
(ADPKD2 or n0nADPKDI) [12]. This report and subsequent
reports [13—15] confirmed genetic heterogeneity in ADPKD,
that is, different gene defects could produce the disorder of
ADPKD. Among the Caucasian population it appears that the
ADPKDI gene (the gene on chromosome 16) accounts for 90%
of ADPKD [16]. Although there appears to be no geographic
clustering of gene types in the Caucasian population, it remains
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Table 1. Advances in ADPKD
Genetic breakthroughs in ADPKD
Localization of an ADPKD gene to chromosome 16
Establishment of genetic heterogeneity
Development of models for studying ADPKD
Culture of ADPKD renal cyst epithelium
MDCK cell-cyst model
cpk Mouse
Metanephric organ culture (cpk mouse)
Information on pathobiology of renal cystogenesis
Increased cellular proliferation
Intracyst polyps
Renal adenoma in ADPKD
Increased growth potential in tissue cultures
Peptide growth factors' alterations
Oncogene promoted cystogenesis
Secretion in cyst formation
cAMP stimulation of MDCK cell cysts"
Reversal of Na-K ATPase polarity
Abnormal extracellular matrix
Pathologic abnormality of cyst basement membrane
Altered basement composition
II
III
aa ab
Fig. 1. Pedigree of an ADPKD family. Clinically affected individuals
are shown as solid symbols. The linkage types are displayed below each
symbol. The affected male in the first generation is dead and his type
has been deduced to be ab. In this family the b type is segregating with
the PKD gene. Thus, in the Ill generation it can be deduced that the aa
offspring (or fetus) has a 95% chance of being unaffected and the ab
offspring (or fetus) has a 95% chance of being affected. Families can be
uninformative in a variety of ways. For example, if the female in
generation I or the unaffected spouse in generation II had been ab, the
likelihood of carrying the ADPKD gene could not be established using
only a single probe. Other marker probes would likely be informative.
to be determined if gene distribution is similar in all racial
groups. The occurrence of genetic heterogeneity has only
modestly complicated the use of gene linkage techniques in
families. The information that one gene is on chromosome 16,
the availability of flanking probes to that gene, and the substan-
tially greater frequency of ADPKD1 versus ADPKD2 permits
assessment of probability of PKD type in a family, and if the
family is ADPKD1 the carrier status of the individuals in
question can still be determined in a majority of families with an
accuracy of 95% or greater.
With the discovery of genetic heterogeneity, the question of
clinical or phenotypic heterogeneity logically followed.
ADPKD, like other autosomal dominant diseases, demon-
strates considerable phenotypic variability. Although Dalgaard
suggested similarity in the age of end-stage renal disease in
family members with ADPKD [171, information on interfamily
variability in ADPKD which would support different genes
producing different clinical syndromes has been lacking. How-
ever, information is now being accumulated that supports
phenotypic variability between the two gene types, suggesting
that ADPKD2 is a milder renal form of the disorder [71. This
could provide a genetic explanation for Dalgaard's clinical
observation of clustering of renal disease severity within fami-
lies. The array and severity of extrarenal manifestations for
ADPKD1 and ADPKD2 remain to be examined. It should also
be emphasized that it is not yet clear that all the so-called
ADPKD2 families are similar; they, in fact, could represent
different genes' defects. Clarification of this point will await
identification of the chromosome carrying the ADPKD2 gene.
These important advances in our understanding of the genet-
ics of ADPKD have not yet permitted us to connect the genetic
mutation to a specific molecular or cellular abnormality which
produces the systemic disorder of ADPKD. However, much
new information has been generated about the major pathobio-
logical processes which participate in renal cystogenesis: aug-
mented cell growth, disordered cellular secretion, and elabora-
tion of an abnormal extracellular matrix. To date, information
has not permitted us to establish which, if any, of these factors
is the primary pathogenetic mechanism in ADPKD. If one of
these abnormalities is ultimately proven to be primary in the
pathogenesis of ADPKD, the genetic defect should be related to
it either directly or indirectly and then the other abnormalities
would be secondary or pan passu events. The potential role of
each of these factors in cystogenesis has been suggested
through pathologic examination of renal tissues, investigations
of animal models of induced and naturally occurring recessive
cystic disease, and cell culture studies of human cystic epithe-
ha.
Pathobiology of cystogenesis
Altered growth
The first observation of altered growth in both human and
animal models of cystic disease was the electron microscopic
finding of cyst wall epithelial cell hyperplasia manifested by
micropolyp formation within the cyst [18]. Subsequent studies
have demonstrated other hyperphastic abnormalities within cyst
walls, including cord-like arrays of hyperplastic epithelium [19].
Moreover, mathematical calculations based on cyst size and
epithehial cell dimensions also support the need for cells to
proliferate in order to form cysts [191. That is, a cyst is not
simply a ballooning of a renal tubule and stretching of cells, but
indeed the result of increased cell numbers.
Further characterization of the exaggerated growth potential
of cystic epithelial cells was obtained from tissue culture
studies. In 1986 Wilson Ct al first successfully cultured human
ADPKD renal cystic epithehium [20]. Primary cultures of
ADPKD cystic epithehia cells showed suggestively increased
ab
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cell growth potential compared to age-matched human renal
proximal straight tubular, thick ascending limb, and cortical
collecting tubular cells in that the ADPKD culture achieved
confluence more rapidly than did the normal epithelial cells
[201. An increased growth capacity was characterized by a
twofold increase in the number of rounds of cell division in the
proliferative phase and a prolonged stationary phase of nine
weeks in ADPKD cyst epithelial cells compared to three weeks
in tubules from both age-matched normal kidneys and end-stage
non-ADPKD kidneys [21]. The exaggerated growth potential of
ADPKD cyst epithelial cells is further underscored by the
ability of these cells to attach and proliferate without matrix on
uncoated plastic—a prerequisite for individually isolated nor-
mal renal tubular cell growth [21]. Of note, other investigators
have not demonstrated an alteration in the rate of epithelial cell
proliferation [22, 23j, an altered life span [23], nor an altered
ability to clone on plastic surfaces [23] in ADPKD epithelia.
However, those studies which fail to demonstrate altered
growth characteristics have used passaged cell cultures rather
than primary cell, and these passaged cells may not accurately
exhibit the true in vivo characteristics of ADPKD epithelium.
Certainly, other cellular characteristics are altered by passaging
of the cells [24]. Moreover, these latter studies have not
compared ADPKD epithelia to age-matched normal tissue
which could alter interpretation of growth characteristics.
Thus, in aggregate, the data suggest that cystogenesis results, at
least in part, from increased cell proliferation. This altered
proliferative capacity should result from a primary or secondary
abnormality in one or more of the factors involved in regulation
of epithelial cell growth, including peptide growth factors,
oncogenes, or cell matrix. In fact, growth promoting alterations
have been identified in ADPKD in all three factors.
Growth factors in ADPKD
Epidermal growth factor, which is a potent mitogen, has been
demonstrated not only to elicit an exaggerated proliferative
response in cultured ADPKD cystic epithelium [22, 25, 26], but
also to be present in ADPKD cyst fluid and cystic epithelium
[25, 27]. In contrast, an inhibitor of renal tubular proliferation,
TGF/3, does not produce the expected inhibition in cultured
ADPKD cystic epithelium [25]. This information suggests that
an alteration between peptide stimulators and inhibitors of cell
growth could contribute to cellular proliferation in ADPKD.
Onco genes in ADPKD
Altered cell growth could be a potential link between an
abnormal genetic message and cystogenesis. Oncogenes which
impart to cells malignant traits, including proliferative capacity,
are a logical target for such a link. Initial studies to pursue the
possible role of oncogenes utilized the CPK mouse, which is a
model for recessive PKD. In this mouse strain homozygotes
develop massively enlarged kidneys riddled with cysts and die
of renal failure in the first month of life [28, 29]. Although this
type of PKD is recessively inherited, relevant information
regarding basic principles of cystogenesis can be derived.
Cowley et at demonstrated a two- to sixfold increase in c-,nyc
RNA at two weeks and an approximately 30-fold increase at
three weeks in the kidneys of the affected CPK mice compared
to normal litter mates [30]. Cowley et al extended these original
observations demonstrating that the elevated oncogene expres-
sion was not limited to c-myc but that mRNA for c-fos and
c-Ki-ras were also increased [31]. As with c-myc mRNA, a
modest elevation at two weeks of age was followed by a more
marked increase at three weeks of age. Although it is tempting
to tie this elevated expression of several oncogenes to the
observed increased cell proliferation in ADPKD, the cell pro-
liferation was not increased to the same degree as was the
oncogene expression; moreover, oncogene mRNA was highest
when proliferation was no longer as marked. Hence these
studies, albeit provocative, did not prove a definitive casual role
for oncogenes in cystogenesis.
Subsequently, transgenic mice studies have furthered the
concept of a causal role for gene-mediated proliferation in
cystogenesis. Studies producing transgenic mice utilizing the
simian virus 40 (SV4O) early region encoding for the either small
and large T antigen or the large T antigen alone manifest renal
cystic disease coupled with tubular cell hyperplasia and other
abnormalities [32—34]. Similarly, a fusion gene consisting of the
SV4O enhancer, the beta globin promoter, and the coding
portion of the murine c-myc gene resulted in transgenic mice
which manifested bilateral renal cystic disease, tubular epithe-
hal cell hyperplasia and in occasional kidneys, microadenomas
[351. Since 100% of these transgenic mice developed renal
cystic disease, the study provides compelling evidence for the
role of oncogenes and/or gene mediated proliferation in cysto-
genesis. However, further studies will be required to define the
relationship of these observations, which substantiate the ca-
pacity of oncogenes to produce cystogenesis, to the actual PKD
gene(s). In these transgenic mice the putative oncogene is in all
cells; however, in at least one study the major defect was
confined to the kidney [34]. This raises the critical question of
how specific cell types are targeted in genetic disorders.
In fact, this question has been raised regarding the cellular
expression of the ADPKD gene: If all cells of an affected
individual contain the defective gene, why is the disorder so
sporadic both within epithelial structures and within the af-
fected organ? The renal cyst involvement in ADPKD dramati-
cally underscores the latter issue. Less than five percent of all
nephrons appear to undergo cystic changes despite the pres-
ence of the gene in all cells [19]. Although similar careful
quantitative dissection studies have not been performed in the
liver, it is likely that a similar distribution of cystic and
non-cystic bile ducts occurs. Moreover, within individual neph-
rons only some segments undergo cystogenesis, and addition-
ally the cystogenic segments vary from nephron to nephron.
Some investigators have observed that this variability in cellu-
lar expression is compatible with the need for a sporadic
additional somatic mutation such as occurs in retinoblastoma
[21; others have suggested that local microenvironmental fac-
tors alter the cellular expression of the gene [23, 36].
Role of secretion in cystogenesis
Given that disordered growth has been demonstrated in some
circumstances in cystic disease it is interesting to note that it is
not confined to cyst formation alone. There is also an increased
frequency of renal adenoma in both human polycystic disease
[37] and the transgenic mouse models [33—35]. The presence of
non-cystic adenoma in ADPKD kidneys suggests the necessity
for a factor in addition to cell proliferation in order for cysto-
genesis to occur. This factor appears to be cellular secretion.
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Cellular proliferation without secretion will produce a tumor or
adenoma, whereas increased cellular proliferation accompanied
by cellular secretion which is accompanied by increased inter-
cyst pressure [38] produces outward expansion yielding a cyst.
The interrelationship of these two processes and the key role of
secretion in cystogenesis have been demonstrated by studies of
Madin-Darby canine kidney (MDCK) cells in culture [38, 39].
McAteer, Evan and Gardner developed a model for cystogen-
esis in which MDCK cells were dispersed within a hydrated
collagen gel [40]. Via clonal growth, single MDCK cells formed
cystic structures polarized with the basolateral surface in con-
tact with the gel and the apical surface facing the cyst lumen
[40]. Of note, only about 7% of MDCK cells cultured in this
manner participate in cyst formation, emphasizing yet again the
heterogeneity in the cellular capacity to initiate cyst formation
[38].
A series of elegant experiments by Mangoo-Karim et al [391,
utilizing subcultures from the cells of a single MDCK cyst
grown by the method of McAteer et al [40], were performed to
identify chemical mediators of secretion in cystogenesis. Pre-
liminary studies lead to a focus on the role of cAMP. In the
absence of stimulation of cAMP or the absence of a cAMP
agonist in the medium, these MDCK cells, endowed with the
capacity for cystogenesis, did not form cysts [39]. With the
addition of 3-isobutyl-l-methylxanthine, a phosphodiesterase
inhibitor, low intracellular levels of cAMP presumably occurred
and cell proliferation was initiated, resulting in balls of cells or
tumors, but not cysts [39]. Compounds such as prostaglandin
E1 (PGEJ) and cholera toxin, which increase intracellular
cAMP substantially, resulted in large fluid-filled cysts [39].
Further evidence for a key role for cAMP was the enhancement
of the effect of each of these compounds on both cyst number
(cell proliferation) and volume (fluid secretion) by the addition
of 3-isobutyl-l-methylxanthine [39].
Additionally, evidence for the role of cAMP in cyst fluid
secretion has been obtained from examination of confluent
monolayers of these MDCK cyst epithelial cells. "Uphill" fluid
secretion against a concentration gradient was demonstrated
when the basolateral surfaces were exposed to agents which
stimulated cAMP [39].
The potential role of cAMP in human cystogenesis is sup-
ported by data from hepatic and renal cyst puncture studies in
patients with ADPKD. In the study by Everson et al three
hepatic and one non-gradient renal cysts were punctured and
the response to intravenous secretin was measured. Two of the
three hepatic cysts and the renal cyst demonstrated increased
fluid secretion within eight minutes of secretin administration
[41]. Although the process by which secretin stimulates epithe-
hal secretion is not entirely delineated, it is known to involve
cAMP [42, 43]. Therefore, both in vitro and in vivo data suggest
a role for stimulation of cAMP in cyst fluid secretion and hence
in cyst growth. This area offers promise for possible modalities
for therapeutic intervention in this disorder.
An additional potential mediator for disordered secretion
relates to abnormalities in the quantity of and location of renal
epithelial Na-K ATPase. Avner et al have delineated the
alterations in renal ATPase in relationship to the stages of
cystogenesis in the CPK mouse [44]. From the beginning of cyst
formation at fetal day 17 to postnatal day 12 (the period of
proximal tubular cysts), total renal ATPase and Na-K ATPase
were increased in cystic kidneys compared to control kidneys
[44]. Furthermore, in a different model, the metanephric organ
culture of the CPK mouse, Na-K ATPase activity induction
with triiodothyronine was associated with sustained proximal
tubular cystogenesis, and conversely Na-K ATPase inhibition
with ouabain prevented sustained cyst formation [45].Addition-
ally, in the MDCK epithelial cell cyst model, ouabain com-
pletely inhibited fluid secretion [39].
Human cystic ADPKD epithelial tissue, both that which has
been recently excised from the cyst wall and that in primary cell
culture, appears to demonstrate altered cellular polarity with
Na-K ATPase located exclusively on the apical rather than the
basolateral cell surface as in normal tubules [46]. Of note, a
variety of other basolateral and apical proteins maintained their
appropriate location. However, actin and the ankyrin-fodrin
complex, which are believed to be involved in the anchoring of
Na-K ATPase in the appropriate membrane, colocalized with
Na-K ATPase at the apical surface in the ADPKD tissue [46].
In this altered location Na-K ATPase appears to maintain its
function, and its reversal in location is accompanied by an
altered direction of cellular sodium transport from the basolat-
eral to the apical cell surface [46]. One can easily imagine how
such altered direction of transport within a blind cyst would
result in cyst enlargement. However, the relationship of this
abnormality to the primary gene defect remains to be deter-
mined. In this regard, although alterations in both proliferation
and secretion appear pivotal to cystogenesis, the relationship of
these abnormalities to the non-cystic systemic manifestations of
ADPKD is difficult to construct. Moreover, as pivotal as
cellular proliferation and secretion are in renal cystogenesis,
there is a caveat in focusing on these processes as primary in
ADPKD. Many congenital disorders [47J, chemical substances
[48], hypokalemia [49] and long-term dialytic therapy [50]all are
associated with renal cysts, suggesting that in this tubular organ
engaged in reabsorption and secretion, cysts may well be a final
common pathway for diverse pathophysiologic insults.
Extra cellular matrix in cysto genesis
The third major abnormality associated with human cystoge-
nesis is an altered extracellular matrix. From a clinical perspec-
tive, a reason for implicating the extracellular matrix in
ADPKD is the array of extrarenal abnormalities. These abnor-
malities have recently been reviewed [51] and include hepatic
cysts [52, 53], cardiac valve abnormalities [54, 55], intracranial
aneurysms [56, 57], hernia formation [51], and perhaps diver-
ticula of the colon [58]. Although a defect in the extracellular
matrix would offer a reasonable explanation for both the
diversity and type of systemic manifestations, the simple pres-
ence of these abnormalities provides no direct evidence for an
extracellular matrix defect. Data supporting the clinical sugges-
tion of a matrix abnormality come from examination of the renal
abnormalities.
Milutinovic noted that renal biopsy specimens from subjects
at risk for ADPKD who later developed detectable cysts
revealed splitting and duplication of the glomerular basement
membranes [59]. Wilson, Hreniuk and Gabow [21] extended an
earlier pathologic observation of Cuppage [60] demonstrating
that the basement membrane surrounding the cysts in ADPKD
kidneys is extraordinarily thickened, up to twenty times the
thickness of normal tubular basement membrane, and appears
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to consist of interwoven fibrils rather than uniformly dense
material, as can be seen with the mild thickening that occurs
with aging.
However, as does the clinical profile, these histologic findings
only provide indirect evidence for altered extracellular matrix
in the pathogenesis of ADPKD. More direct support for a role
of altered extracellular matrix is obtained from ultrastructurat
and compositional changes in the basement membrane of ani-
mal and experimental models of PKD, and from tissue culture
studies of cystic and normal renal epithelium. Ojeda et al have
elegantly depicted the ultrastructural abnormalities that accom-
pany the development and regression of tubular cysts in the
corticosteroid-induced model of cystic disease in newborn
rabbits [61]. Cystic tubular basement membrane contained
increased amounts of ruthenium red staining material (which
may represent proteoglycans), and appeared to have slightly
decreased amounts of immunofluorescent staining for laminin
and type IV collagen compared to basement membrane from
normal control animals. Fibronectin, an extracellular matrix
component found in the interstitium, appeared increased in the
area surrounding the cyst [611.
Carone, Makino and Kanwar found somewhat similar results
utilizing antibodies directed against basement membrane con-
stituents [62]. They compared ADPKD kidneys from humans to
non-ADPKD human kidneys and rat kidneys with toxin-in-
duced cystic disease to normal kidneys from control animals.
Although there were some differences in data from human and
rat tissue, there was loss of reactivity to anti-heparan sulfate
proteoglycans in cyst basement membrane and no change or an
increase in immunofluorescence with anti-type IV collagen and
laminin in cystic kidneys. Fibronectin appeared to be greatly
increased in peritubular areas and in the interstitium. More-
over, in other similar studies Carone documented that the
basement membrane alteration occurred in lockstep with cyst
development, suggesting a causal relationship [63]. However,
Wilson and Sherwood have demonstrated that increased type
IV collagen mRNA occurs late in the course of ADPKD [251.
Others have found alterations in type IV collagen and laminin in
the recessive murine model of PKD. Increased mRNA levels
for collagen IV and lamina were found in the analysis of whole
kidneys of three-week-old cpk mice [64]. This observation was
extended by Taub et al with the demonstration that primary
tissue cultures of kidney epithelial cells of CPK mice display
increased synthesis of collagen IV and laminin and increased
cellular mRNA for the laminin BI chain [65].
Wilson et a! demonstrated that human ADPKD cells in
culture elaborated greater amounts of extraceltular matrix than
did normal human renal proximal and distal tubular epithelia
[20]. Under similar conditions of cell culture confluence,
ADPKD cyst epithelial monolayers incorporated 10- to 15-fold
the amount of radiolabeled inorganic sulfate than did normal
tubules. However, electron microscopy of these cell cultures
revealed that the extracellular matrix had an abnormal appear-
ance. Rather than being a thin layer of material as in normal
epithelial cell cultures, the matrix contained bundles of banded
collagen and spherical accumulation of proteinous material
which stained with ruthenium red, suggesting that at least one
component of the increased matrix was a proteoglycan [201
which may not achieve normal structural characteristics [25].
Granot et al utilized a slightly different culture system to
examine both intracellular and extracellular protein profiles
using 35S-methionine protein radiolabeling and SDS-PAGE
separation for ADPKD cyst epithelial cell culture and for cell
cultures from normal human kidney cortex [22]. A remarkable
similarity existed for the 465 radiolabeled proteins identified.
However, ADPKD cell cultures underexpressed three intracel-
lular proteins and overexpressed six other intracellular pro-
teins. Moreover, ADPKD primary cell cultures produced three
extracellular proteins with apparent molecular weights of 45,
170 and 220 kDa which were not produced by the normal
kidney. Of considerable interest, although primary cultures of
normal human kidney did not elaborate these proteins, multi-
ple-passaged normal cells began to elaborate these same three
proteins, suggesting this altered synthesis in ADPKD epithelia
is an inducible defect.
Thus, all the available data from various models and human
ADPKD do not clearly establish a single uniform alteration in
the extracellular matrix composition; however, taken together,
the data from pathological examination, animal and experimen-
tal models and tissue culture support some type of an alteration
in extracellular matrix in the process of cystogenesis. Initially,
it was hypothesized that this alteration might contribute to cyst
formation via a simple change in the distensibility of the tubular
basement membrane. However, imaginative experiments by
Grantham et al demonstrated unaltered viscoelastic properties
of the basement membrane in experimental cystic disease [66].
It appears more likely that the alteration in extracellular matrix
could contribute to cystogenesis via alterations in cell-matrix
interactions. These interactions are considerable including cell
adhesion [67], cell growth [68], cytodifferentiation [69], and
perhaps gene expression [70]. Thus, if the extracellular matrix
were altered, cell proliferation could be altered as a secondary
event. Similarly, secondary changes in cytodifferentiation could
affect cell polarity, which in turn could alter secretory charac-
teristics of the cell.
Microen vironmental factors
In addition to these three major aspects of cystogenesis a
number of other events may also be operative. For example, it
is obvious that matrix remodelling must occur for cysts to form
in the MDCK model of cyst growth [40]. In this regard it is of
note that the fluid obtained from liver cysts of patients with
ADPKD appear to contain substances capable of modifying
protein structure [41]. These proteins may contribute to matrix
remodelling which would facilitate outward cyst expansion.
Given the paucity of information regarding matrix remodelling,
its role in cystogenesis in human disease has yet to be explored.
Both macro- and microenvironmental factors may also be
capable of modulating cystogenesis. The potential role of the
macroenvironment was demonstrated by studies of Werder,
Gardner and others in which the progression of a naturally
occurring murine model and a toxin-induced cystic disease
could be radically altered by changing the external environment
[71—73]. A germ-free environment significantly ameliorated the
disease, and introduction into the ambient environment or
exposure to endotoxin markedly worsened the development of
cysts in the animals. A role for immune modulators in translat-
ing this environmental effect to the renal microenvironment has
been proposed by Gardner [36]. Sterile cyst fluids from both
hepatic and renal cysts from patients with ADPKD often
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contain large numbers of white cells suggesting an inflammatory
response. Moreover, Gardner et al have demonstrated that cyst
fluid contains an array of cytokines and lymphokines. Sixty-
nine percent of the 94 cysts fluid contained interleukin-1B; 72%
of 75 fluids contained tumor necrosis factor alpha and 30%
contained interleukin-2 [74]. Thus, these immune modulators
could provide macro- and microenvironmetal modulation of
cystogenesis.
However, others have suggested that influence of the mac-
roe nvironment supports the interpretation that PKD is a thresh-
old trait. With a threshold trait, the abnormality appears when
the aggregate effect of the genetic and environmental factors
reach a critical or threshold level. McDonald et al have pre-
sented evidence supporting this concept of a threshold model
for PKD based on studies of multiple strains of mice which
manifested highly variable susceptibility to the cystogenic effect
of glucocorticoid administration [75]. Although this concept
may have relevance to chemically-induced cystic disease, its
relationship to human ADPKD is less clear. One possible
corollary to this concept of a threshold phenomenon which
would be of great interest, if applicable to human disease, is the
possibility of regression of the cystic disease. Kanwar and
Carone have demonstrated marked regression of established
cysts when the toxin is removed in a toxin-induced model in
rats [761. This underscores the potential of reversibility of cystic
disease if putative agents are removed.
Thus, in the last decade our understanding of ADPKD has
advanced substantially in the areas of genetics, clinical mani-
festations and in the pathogenesis of the disorder. An ADPKD
gene has been located on chromosome 16, genetic heterogene-
ity has been established, and a potential role for oncogenes in
cystogenesis has been deduced from experimental data. The
pathobiology of cystogenesis has been extended from our initial
concept of a ballooning tubule filling with glomerular filtrate to
the demonstration of the linked contributions of increased cell
growth and secretion. Data have accumulated demonstrating
abnormal extracellular matrix in both experimental models and
human cystic disease. Despite these significant steps forward
we cannot yet identify the primary defect responsible for
ADPKD. We must continue our efforts to identify the specific
gene abnormalities and the abnormal gene products; to relate
the gene defect to the array of abnormal cellular events in
cystogenesis in order to determine which events are, in fact,
primary and finally we must begin to relate the gene defect not
only to the renal manifestations of this disorder, but also to the
other prominent non-renal clinical abnormalities as well. This
information will ultimately permit us to understand this com-
mon disorder from the gene to the patient.
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